Invitrogen to Increase Focus on Cell Biology Tools; Q3 Revenues Rise 11 Percent | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
An Invitrogen executive said this week that the firm plans greater investments and focus on the cell biology field rather than its traditional molecular biology market.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.